Xenon Pharmaceuticals XENE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$102.3M-57.3% | -$105.26M-60.3% | -$90.9M-44.8% | -$84.71M-46.2% | -$65.05M-35.7% | ||
| $587K-10.9% | $611K-8.3% | $641K-3.9% | $632K-1.4% | $659K+12.5% | ||
| $16.89M+38.8% | $14.12M+3.8% | $13.71M+5.4% | $13.71M-6.8% | $12.17M+29.5% | ||
| $447K+137% | -$1.11M+87.1% | -$701K-118% | -$170K+48.9% | -$1.21M-401% | ||
| -$1.8M+52.4% | $3.19M-48.4% | $5.23M— | $869K-90.5% | -$3.78M+24.6% | ||
| $1.48M+60.0% | —— | $3.37M+451% | $5.49M+673% | $926K+37.6% | ||
| $47K— | $41K— | —— | —— | $0— | ||
| $338K+5.0% | $334K+4.7% | $330K+4.8% | $327K+5.1% | $322K+4.2% | ||
| -$349K-13.7% | -$335K-5.3% | -$337K-7.7% | -$318K-8.5% | -$307K-3.7% | ||
| -$205K-103% | —— | -$283K-441% | -$7.56M-34,455% | $7.18M+18,989% | ||
| -$88.9M-44.2% | -$81.48M-49.8% | -$71.75M-44.5% | -$64.23M-106% | -$61.65M-33.5% | ||
| $133K+209% | $318K-59.4% | $281K-52.4% | $157K-89.6% | $43K-77.1% | ||
| -$407.28M-1,280% | $62.7M-36.4% | $38.53M+7,637% | $82.26M-24.7% | $34.51M+180% | ||
| $5.49M+377% | $1.39M+2,849% | $2.36M— | $65K— | $1.15M— | ||
| $843.01M+73,142% | $113.54M+836% | $2.36M— | $65K— | $1.15M— | ||
| -$130K-103% | —— | —— | $632K+413% | -$64K+82.6% | ||
| $346.7M+1,431% | $94.65M— | -$30.87M+37.2% | $18.72M— | -$26.06M+71.0% | ||
| —— | —— | $1.65M— | —— | —— | ||
| $204K+212% | -$161K+71.4% | $60K+194% | $210K+284% | -$182K-4,450% | ||
| -$349K-13.7% | -$335K-5.3% | -$337K-7.7% | -$318K-8.5% | -$307K-3.7% | ||
| -$205K-103% | —— | -$283K-441% | -$7.56M— | $7.18M— | ||
| $1.48M+60.0% | —— | $3.37M+451% | $5.49M+673% | $926K+37.6% | ||
| $338K+5.0% | $334K+4.7% | $330K+4.8% | $327K+5.1% | $322K+4.2% | ||
| —— | —— | —— | —— | —— | ||
| $837.53M+2,887% | $28.04M+828% | $28.04M+828% | $28.04M+828% | $28.04M+828% | ||
| —— | $5.25M+153% | $5.25M+153% | $5.25M+153% | $5.25M+153% | ||
| $17.64M+746% | —— | $2.24M+65.4% | $8.24M+450% | $2.09M-19.4% | ||
| -$349K-13.7% | -$335K-5.3% | -$337K-7.7% | -$318K-8.5% | -$307K-3.7% | ||
| $439K+4.5% | $434K+1.6% | $435K+2.1% | $425K+4.2% | $420K+2.2% | ||
| —— | —— | —— | —— | —— | ||
| -$89.03M-44.3% | -$81.8M-48.3% | -$72.03M-43.3% | -$64.39M-97.1% | -$61.7M-33.0% | ||
| -$89.03M-44.3% | -$81.8M-48.3% | -$72.03M-43.3% | -$64.39M-97.1% | -$61.7M-33.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Xenon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.